natgillin/translations-raw huggingface dataset:
Your doctor should have prescribed a dose that is appropriate for your weight or your child's weight as follows:
Vaš zdravnik bi moral predpisati odmerek, ki je ustrezen za vašo ali otrokovo telesno maso, kot sledi.
No subject had a QTcF value greater than 500 msec in any of the dosing conditions.
Nobena od oseb ni imela vrednosti QTcF nad 500 msek pod nobenimi pogoji odmerjanja.
If any of the above applies to you or your child or if you are unsure, tell your doctor or pharmacist before taking or giving Eurartesim.
Če kar koli od zgoraj navedenega velja za vas ali vašega otroka ali če ste negotovi, obvestite zdravnika ali farmacevta, preden vzamete ali daste otroku zdravilo Eurartesim.
Tell your doctor if you are in the 1st trimester of pregnancy, think you may be pregnant or become pregnant, or if you are breast-feeding.
Obvestite zdravnika, če ste v 1. trimesečju nosečnosti, menite, da bi lahko bili noseči, načrtujete zanositev ali dojite.
Artenimol bioavailability appears to be higher in malaria patients than in healthy volunteers, possibly because malaria per se has an effect on artenimol disposition.
Kaže, da je biološka razpoložljivost artenimola višja pri bolnikih z malarijo kot pri zdravih prostovoljcih, morda zato, ker ima malarija sama po sebi učinek na razporeditev artenimola.
Therefore the assessment of the potential for drug-drug interactions to occur is based on either in vivo or in vitro studies.
Zato ocene pojava možnosti medsebojnega delovanja med zdravili temeljijo tako na študijah in vivo kot na študijah in vitro.
In each case the results confirmed that Eurartesim was not inferior to the comparator medicinal product.
V obeh primerih so rezultati potrdili, da zdravljenje z zdravilom Eurartesim ni slabše kot s primerjanim zdravilom.
The piperaquine major metabolites were a carboxyl acid cleavage product, and a mono-N-oxidated product.
Glavni presnovki piperakina so bili produkt cepljenja karboksilne kisline in mono-N-oksidiran produkt.
Therefore, caution is advised when administering Eurartesim to these patients (see section 4.4).
Zato je potrebna previdnost pri dajanju zdravila Eurartesim tem bolnikom (glejte poglavje 4.4).
In females delivering normally the development, behaviour and growth of the surviving progeny was normal following exposure in utero or via milk.
Pri samicah, ki so normalno kotile, so razvoj, vedenje in rast preživele zalege po izpostavljenosti in utero ali z mlekom potekali normalno.
Eurartesim should be taken orally with water and without food.
Zdravilo Eurartesim se jemlje z vodo in brez hrane.
There is no data on a second course of treatment.
Ni podatkov o ponovitvi zdravljenja.
You should not take Eurartesim with grapefruit juice due to possible interactions.
Zdravila Eurartesim ne smete jemati s sokom grenivke zaradi možnega medsebojnega delovanja.
This inhibitory effect was no longer evident one week after last administration of Eurartesim.
Ta zaviralni učinek en teden po zadnjem odmerku zdravila Eurartesim ni bil več viden.
• If you or your child is infected more than twice in a year, your doctor will prescribe an alternative treatment.
• Če se vi ali vaš otrok okužite več kot dvakrat v letu, bo vaš zdravnik predpisal drugo zdravljenje.
Absorption of piperaquine is increased in the presence of fatty food (see sections 4.4 and 5.2) which may increase its effect on QTc interval.
Absorpcija piperakina se poveča v prisotnosti mastne hrane (glejte poglavji 4.4 in 5.2), kar lahko poveča njegov učinek na interval QTc.
In vitro metabolism studies demonstrated that piperaquine is metabolised by human hepatocytes (approximately 85% of piperaquine remained after 2 hours incubation at 37°C).
Študije presnove in vitro so pokazale, da piperakin človeški hepatociti presnavljajo (približno 85 % piperakina se po 2 urah inkubacije pri 37 °C ohrani).
You or your child must not take more than two courses within one year.
Vi ali vaš otrok ne smete prejeti več kot dveh ciklov zdravljenja v enem letu.
Eurartesim should not be taken with grapefruit juice as it is likely to lead to increased piperaquine plasma concentrations.
Zdravila Eurartesim se ne sme dajati s sokom grenivke, saj lahko to povzroči višje koncentracije piperakina v plazmi.
Your doctor may take electrical recordings of the heart (electrocardiogram, ECG) while you or your child is being treated and after the last dose is given.
Zdravnik lahko naredi električni posnetek delovanja srca (elektrokardiogram, EKG) med vašim zdravljenjem ali zdravljenjem vašega otroka in po zadnjem odmerku.
In humans, piperaquine has a Tmax of approximately 5 hours following a single and repeated dose.
Pri ljudeh ima piperakin Tmax približno 5 ur po enkratnem in ponavljajočem odmerku.
The mean QTcF prolongation compared to placebo decreased to 11.8 msec at 24 hours and to 7.5 msec at 48 hours.
Povprečno podaljšanje QTcF v primerjavi s placebom se je zmanjšalo na 11,8 msek po 24 urah in na 7,5 msek po 48 urah.
There are no specific data relating to the effects of piperaquine on fertility, however, to date no adverse events have been reported during clinical use.
Ni posebnih podatkov o učinkih piperakina na plodnost, vendar pa v klinični uporabi niso poročali o neželenih učinkih.
Ask your doctor or pharmacist for advice before taking any medicine during pregnancy or breastfeeding.
Posvetujte se z zdravnikom ali farmacevtom, preden vzamete katero koli zdravilo med nosečnostjo ali dojenjem.
No single type of ADR occurred at an incidence of ≥5%.
Nobeni neželeni učinki posamezne vrste se niso pojavili z incidenco ≥ 5 %.
Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, adolescents, children and infants 6 months and over and weighing 5 kg or more.
Zdravilo Eurartesim je indicirano za zdravljenje nezapletene malarije Plasmodium falciparum pri odraslih, mladostnikih, otrocih in dojenčkih, starih 6 mesecev in več in težkih 5 kg ali več.
Effects on cardiac repolarization
Učinki na repolarizacijo srca
It is used to treat uncomplicated malaria when use of a medicine given by mouth is appropriate.
Uporablja se za zdravljenje nezapletene malarije, ko je peroralno dajanje zdravila ustrezno.
Therefore, they may be more sensitive to the effects of QTc-prolonging medications such as Eurartesim so that special caution is required.
Zato so morda bolj občutljivi na učinke zdravil, ki podaljšujejo interval QTc, kot je zdravilo Eurartesim, zaradi česar je potrebna posebna pozornost.
When clinically appropriate, consideration should be given to obtaining an ECG from all patients before the last of the three daily doses is taken and approximately 4-6 hours after the last dose, since the risk of QTc interval prolongation may be greatest during this period (see section 5.2).
Če je klinično ustrezno, je treba razmisliti o pridobitvi EKG posnetka od vseh bolnikov pred uporabo zadnjega od treh dnevnih odmerkov in v približno 4-6 urah po zadnjem odmerku, saj je lahko tveganje za podaljšanje intervala QTc v tem obdobju največje (glejte poglavje 5.2).
Therefore Eurartesim must not be used in the 1st trimester of pregnancy if your doctor can give you an alternative medicine.
Zato se zdravila Eurartesim ne sme uporabljati v 1. trimesečju nosečnosti, če vam zdravnik lahko predpiše drugo zdravilo.
Eurartesim should not be used to treat severe falciparum malaria (see section 4.3) and, due to insufficient data, should not be used to treat malaria due to Plasmodium vivax, Plasmodium malariae or Plasmodium ovale.
Zdravila Eurartesim se ne sme uporabljati za zdravljenje hude oblike malarije, ki jo povzroča plazmodij P. falciparum (glejte poglavje 4.3), zaradi nezadostnih podatkov pa se ga prav tako ne sme uporabljati za zdravljenje malarije, povzročene s plazmodiji Plasmodium vivax, Plasmodium malariae ali Plasmodium ovale.
Tablet strength and number of tablets per dose
Jakost tablete in število tablet na odmerek
This may reflect malaria-associated impairment of hepatic function, causing an increase in artenimol bioavailability (reduction of first hepatic effect) without affecting its apparent elimination half-life, which is absorption rate limited.
To se lahko odraža z malarijo povezano okvaro delovanja jeter, ki povzroči povečanje biološke razpoložljivosti artenimola (zmanjšanje prvega jetrnega učinka), ne da bi to vplivalo na navidezno razpolovno dobo izločanja, ki je omejena z absorpcijsko stopnjo.
Due to its slow elimination, piperaquine accumulates in plasma after multiple doses with an accumulation factor of approximately 3.
Zaradi počasnega izločanja se piperakin kopiči v plazmi po večkratnem odmerjanju s faktorjem akumulacije približno 3.
There is potential for neurotoxicity of artemisinin derivatives in man and animals, which is strongly related to the dose, route and formulations of the different artenimol pro-drugs.
Obstaja možnost za nevrotoksičnost derivatov artemizinina pri ljudeh in živalih, ki je močno odvisen od odmerka, poti uporabe in formulacije različnih predzdravil artenimola.
In a paediatric pharmacokinetic study, and based on very limited sampling, minor differences were observed for artenimol pharmacokinetics between the paediatric and adult populations.
V pediatrični študiji farmakokinetike in na podlagi majhnega vzorca so opazili manjše razlike za farmakokinetiko artenimola med pediatrično in odraslo populacijo.
A course of Eurartesim lasts 3 consecutive days.
Zdravljenje z zdravilom Eurartesim traja tri zaporedne dni.
• The need to counsel patients on important risks associated with Eurartesim therapy and appropriate precautions when using the medicine.
• Bolnikom je treba svetovati o pomembnih tveganjih, povezanih z zdravljenjem z zdravilom Eurartesim, in o ustreznih previdnostnih ukrepih med uporabo zdravila.
The safety and efficacy of Eurartesim in infants aged less than 6 months and in children weighing less than 5 kg has not been established.
Varnost in učinkovitost zdravila Eurartesim pri dojenčkih, starih manj kot 6 mesecev, in pri otrocih s telesno maso, manjšo kot 5 kg, nista bili dokazani.
Since piperaquine is present in the skin (about 9% in the non-pigmented rat and only 3% in the pigmented rat), slight phototoxic reactions (swelling and erythema) were observed 24 hours after oral treatment in mice exposed to UV radiation.
Ker je piperakin prisoten v koži (približno 9 % v nepigmentiranih podganah in le 3 % v pigmentiranih podganah), so opazili rahle fototoksične reakcije (oteklost in eritem) 24 ur po peroralnem dajanju mišim, izpostavljenim UV-žarkom.
The most important nonclinical safety findings after repeated dosing were the infiltration of macrophages with intracytoplasmic basophilic granular material consistent with phospholipidosis and degenerative lesions in numerous organs and tissues.
Najpomembnejši predklinični izsledek o varnosti po ponavljajočem se odmerjanju je bila infiltracija makrofagov z intracitoplazemskim bazofilnim granularnim materialom, konsistentna s fosfolipidozo in degenerativnimi lezijami številnih organov in tkiva.
There was no evidence of artenimol-induced lesions in the specific nuclei in rats or dogs, even at lethal dose.
Ni dokazov o lezijah, induciranih z artenimolom, v specifičnih jedrih podgan ali psov, tudi ob smrtnih odmerkih.
Tell your doctor or pharmacist if you or your child is taking, has recently taken or might take any other medicines.
Obvestite zdravnika ali farmacevta, če vi ali vaš otrok jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
QTc intervals of more than 500 ms are associated with a pronounced risk for potentially life-threatening ventricular tachyarrhythmias.
Intervali QTc, višji od 500 ms, so povezani z izrazitim tveganjem ventrikularne tahiaritmije, ki so lahko življenjsko nevarne.
In humans, the potential neurotoxicity of orally administered artenimol can be considered highly unlikely, given the rapid clearance ofartenimol, and its short exposure (3 days of treatment for malaria patients).
Pri ljudeh je možnost nevrotoksičnosti peroralno uporabljenega artenimola zelo malo verjetna, ob upoštevanju hitrega očistka artenimola in kratke izpostavljenosti (3 dni za zdravljenje bolnikov z malarijo).
In a randomised trial in which 767 adults and children with uncomplicated P. falciparum malaria were exposed to Eurartesim, 25% of subjects were judged to have experienced an adverse drug reaction
V randomizirani študiji, v kateri je bilo 767 odraslih in otrok z nezapleteno malarijo P. falciparum izpostavljenih zdravilu Eurartesim, so ocenili, da je imelo 25 % oseb neželene učinke na zdravilo Eurartesim.
In perinatal and postnatal studies in rats, piperaquine was associated with delivery complications.
V perinatalnih in postnatalnih študijah pri podganah so piperakin povezali z zapleti med kotenjem.
If you or your child is not able to do this, talk to your doctor or pharmacist.
Če vi ali vaš otrok tega niste sposobni, se pogovorite z zdravnikom ali farmacevtom.
Pharmacokinetic parameters observed for piperaquine in humans indicate that this active substance has a large volume of distribution (730 l/kg; CV 37.5%).
Farmakokinetični parametri, ki so jih opazili za piperakin pri ljudeh, kažejo, da ima ta učinkovina velik volumen porazdelitve (730 l/kg; CV 37,5 %).
The effect on prolongation of the QTc interval was observed on Day 2, and had resolved by Day 7 (the next time point at which ECGs were performed).
Učinek na podaljšanje intervala QTc so opazili 2. dan, do 7. dne pa so izzveneli (naslednja časovna točka izvajanja EKG).
Literature data concerning chronic toxicity of piperaquine in dogs and monkeys indicate some hepatotoxicity and mild reversible depression of total white cell and neutrophil counts.
Podatki iz literature glede kronične toksičnosti piperakina pri psih in opicah kažejo na hepatotoksičnost in blago reverzibilno depresijo skupnega števila levkocitov in nevtrofilcev.
The above mentioned interactions for adults and the warnings in section 4.4 should be taken into account for the paediatric population.
Pri pediatrični populaciji je treba upoštevati zgoraj omenjena medsebojna delovanja pri odraslih in opozorila v poglavju 4.4.
Each dose should be taken no less than 3 hours after the last food intake.
Vsak odmerek je treba vzeti vsaj 3 ure po zadnjem zaužitju hrane.
The medicine can be taken by adults, adolescents, children and infants over 6 months old who weigh 5 kilograms or more.
Zdravilo lahko jemljejo odrasli, mladostniki, otroci in dojenčki, stari več kot 6 mesecev, s telesno maso 5 kilogramov ali več.
There is the potential for reducing the rate of metabolism of other substrates of this enzyme, such as omeprazole, with consequent increase of their plasma concentration, and therefore, of their toxicity.
Ima potencial za zmanjšanje stopnje presnavljanja drugih substratov tega encima, na primer omeprazola, s posledičnim zvišanjem njihovih koncentracij v plazmi in s tem njihove toksičnosti.
Its endoperoxide bridge is thought to be essential for its antimalarial activity, causing free-radical damage to parasite membrane systems including:
Prevladuje mnenje, da je njegov endoperoksidni most bistven za njegovo antimalarično aktivnost, ker s prostimi radikali poškoduje membranski sistem parazita, vključno s/z:
However, the apparent clearance was faster (1.30 versus 1.14 l/h/kg) and the apparent total volume of distribution was lower in the paediatric population (623 versus 730 l/kg).
Vendar pa je bil navidezni očistek hitrejši (1,30 v primerjavi z 1,14 l/h/kg) in navidezni skupni volumen porazdelitve nižji v pediatrični populaciji (623 v primerjavi s 730 l/kg).
Chloroquine binds to toxic haeme (derived from the patient's haemoglobin) within the malaria parasite, preventing its detoxification via a polymerisation step.
Klorokin se veže na toksične heme (izpeljane iz bolnikovega hemoglobina) znotraj malaričnega parazita, kar preprečuje njegovo detoksifikacijo s polimerizacijskim korakom.
In the absence of carcinogenicity study data, and due to lack of clinical experience with repeated courses of treatment in humans, no more than two courses of Eurartesim should be given in a 12-month period (see sections 4.2 and 5.3).
Zaradi pomanjkanja podatkov študij kancerogenosti in zaradi pomanjkanja kliničnih izkušenj s ponavljanjem ciklov zdravljenja pri ljudeh ni mogoče priporočiti več kot dva cikla zdravljenja z zdravilom Eurartesim v 12-mesečnem obdobju (glejte poglavji 4.2 in 5.3).
Reactions such as cough, pyrexia, headache, P. falciparum infection, anaemia, asthenia, anorexia and the observed changes in blood cell parameters are consistent with those expected in patients with acute malaria.
Reakcije, kot so kašelj, pireksija, glavobol, okužba s P. falciparum, anemija, astenija, anoreksija in opažene spremembe parametrov krvnih celic so bile konsistentne s pričakovanimi za bolnike z akutno malarijo.
Side effects in adults
Neželeni učinki pri odraslih
30.400 00071 Pomezia (Rome) Italy
30,400 00071 Pomezia (Rim) Italija
Taking this medicine, if the malaria infection returns
Jemanje zdravila pri ponovitvi okužbe z malarijo
Via Pontina Km 30.400 IT-00071 Pomezia (RM) Italy
Via Pontina Km 30.400 IT-00071 Pomezia (RM) Italija
Reproductive studies with artemisinin derivatives have demonstrated teratogenic potential with an increased risk during early gestation (see section 5.3).
Študije vpliva na razmnoževanje z derivati artemizinina so pokazale teratogeni potencial z zvečanim tveganjem v zgodnji nosečnosti (glejte poglavje 5.3).
Piperaquine has the potential to increase the rate of metabolism for CYP2E1 substrates resulting in a decrease in the plasma concentrations of substrates such as paracetamol or theophylline, and the anaesthetic gases enflurane, halothane and isoflurane.
Piperakin ima potencial za zviševanje stopnje presnove za substrate encima CYP2E1, kar povzroči zmanjšanje koncentracij v plazmi za substrate kot so paracetamol ali teofilin in plini za anestezijo enfluran, halotan in izofluran.
Women taking Eurartesim should not breast-feed during their treatment.
Ženske, ki jemljejo zdravilo Eurartesim, naj med zdravljenjem ne dojijo.
Considering the possibility of age-associated decrease in hepatic and renal function, as well as a potential for heart disorders (see sections 4.3 and 4.4), caution should be exercised when administering the product to the elderly.
Ob upoštevanju možnosti s starostjo povezanega zmanjšanja delovanja jeter in ledvic ter možnosti za bolezni srca (glejte poglavji 4.3 in 4.4) je potrebna pri dajanju tega zdravila starejšim bolnikom previdnost.
diazepam, alprazolam), zaleplon, zolpidem;
alprazolam, zaleplon, zolpidem),
ANNEX II A MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA
Eurartesim has not been evaluated in patients with moderate or severe renal or hepatic insufficiency (see section 4.2).
Zdravilo Eurartesim ni bilo ovrednoteno pri bolnikih z zmerno ali hudo ledvično ali jetrno insuficienco (glejte poglavje 4.2).
Analysis of cardiac adverse events in clinical trials showed that these were reported more frequently in Eurartesim treated patients than in those treated with comparator antimalarial (see section 4.8).
Analiza srčnih neželenih učinkov v teh kliničnih preskušanjih je pokazala, da so bili poročani pogosteje pri bolnikih, zdravljenih z zdravilom Eurartesim, kot pri bolnikih, zdravljenih s primerljivimi antimalariki (glejte poglavje 4.8).
If you or your child vomit also the second dose, do not take or give your child another dose.
Če vi ali vaš otrok izbruhate tudi drugi odmerek, ne vzemite še enega ali otroku ne dajte še enega.
What Eurartesim is and what it is used for What you need to know before you or your child takes Eurartesim How to take Eurartesim
Kaj je zdravilo Eurartesim in za kaj ga uporabljamo Kaj morate vedeti, preden boste vi ali vaš otrok vzeli zdravilo Eurartesim Kako jemati zdravilo Eurartesim
Animal data suggest excretion of piperaquine into breast milk but no data are available in humans.
Podatki na živalih kažejo, da se piperakin izloča v mleko, vendar za ljudi ni na voljo podatkov.
These patients should not receive another dose of Eurartesim and alternative antimalarial therapy should be instituted.
Ti bolniki ne smejo prejeti še drugega odmerka zdravila Eurartesim, temveč se naj začnejo zdraviti z alternativnim antimalarikom.
Animal studies showed that radiolabelled piperaquine is excreted by the biliary route, while urinary excretion is negligible.
Študije na živalih so pokazale, da se radioaktivno označen piperakin izloča prek žolča, medtem ko je izločanje v urinu zanemarljivo.
Artenimol and piperaquine were not genotoxic/clastogenic based on in vitro and in vivo testing.
Artenimol in piperakin nista bila genotoksična/klastogena v preskušanjih in vitro in in vivo.
The ADRs noted for Eurartesim were generally mild in severity, and the majority were non-serious.
Neželeni učinki, ki so jih opazili pri jemanju zdravila Eurartesim, so bili na splošno blagi in večinoma niso bili resni.
The association of artenimol and piperaquine does not produce hERG inhibition greater than that of the single compounds.
Povezava artenimola in piperakina ne povzroči večjega zaviranja hERG kot pri eni sami sestavini.
In the European Safety Registry 25 patients weighing ≥ 100 kg (range 100 -121 kg) were treated with 4 tablets 320/40 mg PQP/artenimol for 3 days.
V evropski študiji varnosti so 25 bolnikov s telesno maso ≥ 100 kg (razpon od 100 kg do 121 kg) 3 dni zdravili s 4 tabletami 320 mg/40 mg PKP/artenimola.
The age-specific PCR-corrected cure rates in the m-ITT populations are tabulated below for the Asian and African studies, respectively:
Za starost specifične stopnje ozdravljenja, popravljene za PCR, v populacijah m-ITT za študiji v Aziji in Afriki, so predstavljene v spodnji tabeli:
Artenimol administration may result in a slight decrease in CYP1A2 activity.
Dajanje artenimola lahko povzroči rahlo zmanjšanje aktivnosti encima CYP1A2.
The bulky bisquinolone structure may be important for activity against chloroquine- resistant strains, and may act through the following mechanisms:
Obsežna zgradba biskinolona je morda pomembna pri aktivnosti proti sevom, odpornim na klorokin, in lahko deluje preko naslednjih mehanizmov:
Piperaquine is a bisquinoline, and this class has shown good antimalarial activity against chloroquineresistant Plasmodium strains in vitro.
Piperakin je biskinolon in ta razred kaže in vitro dobro antimalarično aktivnost proti sevom plazmodija, odpornim na klorokin.
Resistance to piperaquine (when used as monotherapy) has been reported.
Poročali so o odpornosti na piperakin (če se uporablja kot monoterapija).
In a second randomised trial, 1,038 children, aged between 6 months and 5 years, were exposed to Eurartesim and 71% were judged to have experienced an ADR.
V drugem randomiziranem preskušanju je bilo zdravilu Eurartesim izpostavljenih 1.038 otrok, starih med 6 meseci in 5 let, in ocenjeno je bilo, da je imelo 71 % preiskovancev neželene učinke.
Other medicines and Eurartesim
Druga zdravila in zdravilo Eurartesim
The number of subjects with QTcF greater than 480 msec after dosing with low fat meals was 3/64, while 10/64 had QTcF values over this threshold after dosing with high fat meals.
Število oseb s QTcF, višjim od 480 msek, po odmerjanju z obroki z nizko vsebnostjo maščob je bil 3/64, medtem ko jih je imelo 10/64 vrednosti QTcF nad tem pragom po odmerjanju z obroki z visoko vsebnostjo maščob/kalorij.
The QTcF prolongation observed under fasting conditions lasted between 4 and 11 hours after the last dose was administered on Day 3.
Podaljšanje QTcF, ki so ga opazili na tešče, je trajalo med 4 in 11 ur po dajanju zadnjega odmerka 3. dne.
Sometimes a problem with your red blood cells, called haemolytic anaemia can occur after receiving malaria treatment.
Včasih se lahko po zdravljenju malarije pojavi težava z vašimi rdečimi krvnimi celicami, imenovana hemolitična anemija.